Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imipenem/Cilastatin-XNW4107 vs Imipenem/Cilastatin/Relebactam in HABP/VABP
2022-501952-27-00Phase 3Completed
- Sponsor
- Evopoint Biosciences
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial of pibozobactam in hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) and Gram-negative bacterial infection (2 arms), sponsored by Evopoint Biosciences. Primary endpoint: Day 14 all-cause mortality rate in the MITT population. Started May 2023; status: completed.
02
Drugs
pibozobactam
03
Conditions
hospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)Gram-negative bacterial infection
Beyond the preview
Go deeper on 2022-501952-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501952-27-00.